Acalabrutinib + Lenalidomide + Rituximab + Obinutuzumab

Phase 2Active

0 views this week 0 watching💤 Quiet

Interest: 39/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Mantle Cell Lymphoma

Conditions

Mantle Cell Lymphoma

Trial Timeline

Oct 11, 2019 → Sep 1, 2027

NCT ID

NCT03863184

About Acalabrutinib + Lenalidomide + Rituximab + Obinutuzumab

Acalabrutinib + Lenalidomide + Rituximab + Obinutuzumab is a phase 2 stage product being developed by AstraZeneca for Mantle Cell Lymphoma. The current trial status is active. This product is registered under clinical trial identifier NCT03863184. Target conditions include Mantle Cell Lymphoma.

What happened to similar drugs?

1 of 6 similar drugs in Mantle Cell Lymphoma were approved

Approved (1) Terminated (1) Active (4)

✅Acalabrutinib capsuleAstraZenecaApproved

🔄Pirtobrutinib + Ibrutinib + Acalabrutinib + ZanubrutinibEli LillyPhase 3

🔄Rituximab 375 mg/m^2 + Cyclophosphamide 750 mg/m^2 + Doxorubicin 50 mg/m^2 + VELCADE 1.3 mg/m^2 + Prednisone 100 mg/m^2 + Vincristine 1.4 mg/m^2Johnson & JohnsonPhase 3

🔄Acalabrutinib + Bendamustine + Rituximab + PlaceboAstraZenecaPhase 3

🔄Sonrotoclax + Zanubrutinib + PlaceboBeOne MedicinesPhase 3

❌parsaclisib + rituximab + bendamustine + PlaceboIncytePhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03863184	Phase 2	Active	Oct 11, 2019	Sep 1, 2027	Mantle Cell Lymphoma

Competing Products

20 competing products in Mantle Cell Lymphoma

See all competitors

Product	Company	Stage	Hype Score
Pirtobrutinib + Brexucabtagene Autoleucel	Eli Lilly	Phase 2	42
Obinutuzumab + Glofitamab + Pirtobrutinib	Eli Lilly	Phase 2	42
enzastaurin	Eli Lilly	Phase 2	35
Abemaciclib	Eli Lilly	Phase 2	35
Pirtobrutinib + Ibrutinib + Acalabrutinib + Zanubrutinib	Eli Lilly	Phase 3	44
Pirtobrutinib + Rituximab + Venetoclax	Eli Lilly	Phase 2	42
Pirtobrutinib and rituximab	Eli Lilly	Phase 2	42
gemcitabine + mitoxantrone + rituximab	Eli Lilly	Phase 2	35
Rituximab 375 mg/m^2 + Cyclophosphamide 750 mg/m^2 + Doxorubicin 50 mg/m^2 + VELCADE 1.3 mg/m^2 + Prednisone 100 mg/m^2 + Vincristine 1.4 mg/m^2	Johnson & Johnson	Phase 3	40
Venetoclax	AbbVie	Phase 2	35
Ibrutinib + Venetoclax	AbbVie	Phase 2	35
ABT-199 and Ibrutinib Combination	AbbVie	Phase 1	29
Venetoclax Oral Tablet [Venclexta]	AbbVie	Phase 2	27
Acalabrutinib capsule	AstraZeneca	Approved	43
Acalabrutinib in combination with BR + Acalabrutinib in combination with VR	AstraZeneca	Phase 1	33
Acalabrutinib + Venetoclax + Obinutuzumab	AstraZeneca	Phase 1/2	39
Acalabrutinib + R-CHOP standard of care + Acalabrutinib combination with Rituximab + Acalabrutinib monotherapy	AstraZeneca	Phase 2	42
Acalabrutinib + Venetoclax + Rituximab	AstraZeneca	Phase 2	39
Acalabrutinib + Rituximab	AstraZeneca	Phase 2	42
Acalabrutinib Treatment A + Acalabrutinib Treatment B + Acalabrutinib Treatment C + Acalabrutinib Treatment D	AstraZeneca	Phase 1	29